Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine

Vaccine

Volumn 30, Issue 30, 2012, Pages 4543-4551

  Ehrlich, Hartmut J ^a   Müller, Markus ^b   Kollaritsch, Herwig ^c   Pinl, Fritz ^d   Schmitt, Bernhard ^e   Zeitlinger, Markus ^b   Loew Baselli, Alexandra ^a   Kreil, Thomas R ^a   Kistner, Otfried ^a   Portsmouth, Daniel ^a   Fritsch, Sandor ^a   Maritsch, Friedrich ^a   Aichinger, Gerald ^a   Pavlova, Borislava G ^a   Barrett, P Noel ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Sanatorium Leech   (Austria)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

H1N1; Influenza; Pandemic; Vaccine; Vero

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS REACTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VERO CELLS; YOUNG ADULT;

EID: 84862004737     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.061     Document Type: Article

References (50)

1. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011, 29:1135-1138.
2. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3-17 years of age. N Engl J Med 2010, 362:370-372.
3. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
4. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
5. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
6. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
7. Roman F., Vaman T., Kafeja F., Hanon E., Van D.P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51:668-677.
8. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
9. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
10. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
11. A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2009, 2:1740-1745.
12. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
13. Gasparini R., Schioppa F., Lattanzi M., Barone M., Casula D., Pellegrini M., et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 2010, 64:432-438.
14. Jackson L.A., Patel S.M., Swamy G.K., Frey S.E., Creech C.B., Munoz F.M., et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011, 204:854-863.
15. Torii Y., Kimura H., Ochi N., Kaneko K., Ando H., Kiuchi T., et al. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients. Vaccine 2011, 29:4187-4189.
16. Lagler H., Wenisch J.M., Tobudic S., Gualdoni G.A., Rodler S., Rasoul-Rockenschaub S., et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 2011, 29:6888-6893.
17. Safety of pandemic A (H1N1) influenza vaccines. WHO, 2011. Available from: http://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/Jun_2010/en/index.html.
18. Cheng A.C., Kotsimbos T., Kelly H.A., Irving L.B., Bowler S.D., Brown S.G., et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine 2011, 29:7320-7325.
19. Mahmud S., Hammond G., Elliott L., Hilderman T., Kurbis C., Caetano P., et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011, 29:7975-7981.
20. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2011.
21. Song J.Y., Cheong H.J., Heo J.Y., Noh J.Y., Choi W.S., Park D.W., et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 2011, 29:1395-1398.
22. Wu J., Xu F., Lu L., Lu M., Miao L., Gao T., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010, 363:2416-2423.
23. Bautista E., Chotpitayasunondh T., Gao Z., Harper S.A., Shaw M., Uyeki T.M., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719.
24. Girard M.P., Tam J.S., Assossou O.M., Kieny M.P. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 2010, 28:4895-4902.
25. Butler D. Portrait of a year-old pandemic. Nature 2010, 464:1112-1113.
26. Shrestha S.S., Swerdlow D.L., Borse R.H., Prabhu V.S., Finelli L., Atkins C.Y., et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-2010). Clin Infect Dis 2011, 52(Suppl. 1):S75-S82.
27. Broberg E., Nicoll A., Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus-where are we. Clin Vaccine Immunol 2011, 18:1205-1212.
28. Booy R., Khandaker G., Heron L.G., Yin J., Doyle B., Tudo K.K., et al. Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. Med J Aust 2011, 194:19-23.
29. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
30. Ikonen N., Strengell M., Kinnunen L., Osterlund P., Pirhonen J., Broman M., et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 2010, 15.
31. Skowronski D.M., Hottes T.S., McElhaney J.E., Janjua N.Z., Sabaiduc S., Chan T., et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011, 203:158-167.
32. McCullers J.A., Van D.V., Allison K.J., Branum K.C., Webby R.J., Flynn P.M. Recipients of vaccine against the 1976 swine flu have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010, 50:1487-1492.
33. Hardelid P., Andrews N.J., Hoschler K., Stanford E., Baguelin M., Waight P.A., et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010, 14:115-192.
34. Committee for Medicinal Products for Human Use (CHMP). Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). European Medicines Agency, 2008. Report No.: EMEA/CPMP/VEG/4717/2003-Rev.1.
35. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, 1997. Report No.: CPMP/BWP/214/96.
36. Kistner O., Crowe B.A., Wodal W., Kerschbaum A., Savidis-Dacho H., Sabarth N., et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 2010, 5:e9349.
37. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5:237-247.
38. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. FDA; 2011. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf.
39. Bidwell E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927, 22:209-212.
40. Bericht zur Epidemiologie der Influenza in Deutschland Saison 2009/10. Robert Koch Institut; 2011. Available from: http://influenza.rki.de/Saisonberichte/2009.pdf.
41. Influenza in österreich, Saison 2009/2010. Austrian Agency for Food and Health Safety (AGES) Nationale Referenzzentrale für Influenza-Epidemiologie; 2011. Available from: http://www.ages.at/uploads/media/Microsoft_Word_-_Influenza_Jahresbericht_2009_20010pup_02.PDF.
42. Ehrlich H.J., Müller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
43. Ehrlich H.J., Muller M., Fritsch S., Zeitlinger M., Berezuk G., Low-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.
44. Twenty-second pandemic pharmacovigilance update. European Medicines Agency, 2010. Report No.: EMA/527985/2010.
45. Kunzel W., Glathe H., Engelmann H., Van H.C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996, 14:1108-1110.
46. Tang J.W., Tambyah P.A., Wilder-Smith A., Puong K.Y., Shaw R., Barr I.G., et al. Cross-reactive antibodies to pandemic (H1N1) 2009 virus, Singapore. Emerg Infect Dis 2010, 16:874-876.
47. Wood J.M., Gaines-Das R.E., Taylor J., Chakraverty P. Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12:167-174.
48. Wang W., Anderson C.M., De Feo C.J., Zhuang M., Yang H., Vassell R., et al. Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog 2011, 7:e1002081.
49. Labrosse B., Tourdjman M., Porcher R., LeGoff J., de L.X., Simon F., et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS ONE 2010, 5:e11036.
50. Lemaitre M., Leruez-Ville M., De Lamballerie X.N., Salez N., Garrone P., Fluckiger A.C., et al. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clin Microbiol Infect 2010.